throbber
Eye Therapies Exhibit 2129, 1 of 4
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`7/8/22, 9:56 AM
`
`Slayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsule…
`Ajay Singh, CEO of Slayback Pharma, said, "Slayback's launch has triggered
`the 180-day CGT exclusivity period for Merzee. We continue to remain
`focused on bringing high quality and affordable generics to the US market."
`
`Merzee is available for shipment and can be ordered through your
`wholesaler/distributor.  Please contact our customer service team at 1-844-
`566-2505.
`
`See the following important safety information and refer to the package
`insert for full prescribing information.
`
`What is Merzee Used for?
`Merzee is an oral estrogen/progestin combination oral contraceptive (COC)
`used by women to prevent pregnancy.  One capsule is taken daily in order
`as provided in the blister pack. The efcacy of Merzee in women who are
`obese (mass index (BMI) of > 35 kg/m ) has not been evaluated .
`2
`1
`
`Important Safety Information for Merzee
`
`WARNING CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
`See Full Prescribing Information for complete boxed warning.
`• Women over 35 years old who smoke should not use Merzee.
`• Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive
`(COC) use.
`
`Do not use Merzee if you:
`
`have had blood clots, a heart attack or stroke, uncontrolled high blood
`pressure
`have liver tumors or liver disease
`have unexplained vaginal bleeding
`are pregnant
`have had breast cancer or other estrogen- or progestin-sensitive
`cancer
`are taking Hepatitis C drugs containing ombitasvir/
`paritaprevir/ritonavir, with or without dasabuvir
`Allergic to any of the ingredients in Merzee
`
`
`
`
`
`
`
`
`
`
`
`
`Stop using and discuss with your doctor before restarting:
`
`https://www.prnewswire.com/news-releases/slayback-pharma-announces-launch-of-merzee-norethindrone-acetate-and-ethinyl-estradiol-capsules-and… 2/4
`
`Eye Therapies Exhibit 2129, 2 of 4
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`7/8/22, 9:56 AM
`
`
`
`Slayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsule…
`if a blood clotting occurs or an unexplained change or loss of vision
`occurs.
`at least 4 weeks before through 2 weeks after major surgery. Start no
`earlier than 4 weeks after delivery, or if you are breastfeeding.
`if you develop liver disease or yellowing of the shin or eyes occurs.
`if you have a history of or develop problems with your gallbladder
`if you are prediabetic or diabetic and should be monitored by your
`doctor
`have uncontrolled carbohydrate and lipid (fat) metabolic effects,
`discuss an alternative method of birth control with your doctor.
`if you have signicant changes in headaches.
`if you have unusual or absent vaginal bleeding
`
`
`
`
`
`
`
`
`
`
`
`
`Possible side effects
`The most serious adverse events or side effects which could be life-
`threatening or lead to permanent disability are:
`
`cardiovascular events such as heart attack and stroke
`vascular problems such as clotting in lungs and deep veins
`liver disease
`
`
`
`
`
`The most common adverse reactions reported are:
`
`irregular vaginal bleeding
`nausea
`breast tenderness
`headache
`
`
`
`
`
`
`Merzee may cause decreased milk production in breastfeeding women.
`
`In clinical trials the most common reported side effects were: headache,
`vaginal infections, nausea, menstrual cramps, breast tenderness, bacterial
`vaginitis, abnormal cervical smear, acne, mood swings, and weight gain.
`
`Drug Interactions
`Drugs like Merzee have seriously decreased the effects of thyroid hormone
`replacement drugs and lamotrigine. Do not take Merzee with hepatitis
`drugs containing ombitasvir/ paritaprevir/ritonavir, with or without
`dasabuvir.
`
`Drugs or herbal products that trigger certain enzymes, including CYP3A4,
`may decrease the effectiveness of drugs like Merzee or increase
`breakthrough bleeding. Patients should use a back-up method or
`
`https://www.prnewswire.com/news-releases/slayback-pharma-announces-launch-of-merzee-norethindrone-acetate-and-ethinyl-estradiol-capsules-and… 3/4
`
`Eye Therapies Exhibit 2129, 3 of 4
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`7/8/22, 9:56 AM
`
`Slayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsule…
`alternative method of contraception when these products are used with
`Merzee and other COCs.
`
`You may report an adverse event related to Merzee made by Slayback
`Pharma by calling 1-844-566-2505 or emailing medical@slayback-
`pharma.com.  If you prefer, you may contact the U.S. Food and Drug
`Administration (FDA) directly at fda.gov/medwatch or call 1-800-FDA-1088.
`
`References:
`Merzee full Prescribing Information . Slayback Pharma, 01/2021
`(1)
`Taytulla® is a registered trademark of Allergan Pharmaceuticals
`International Limited
`
`SOURCE Slayback Pharma LLC
`
`Related Links
`http://www.slayback-pharma.com
`
`https://www.prnewswire.com/news-releases/slayback-pharma-announces-launch-of-merzee-norethindrone-acetate-and-ethinyl-estradiol-capsules-and… 4/4
`
`Eye Therapies Exhibit 2129, 4 of 4
`Slayback v. Eye Therapies - IPR2022-00142
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket